AML consolidation using Allogeneic Transplant

Matched-Pairs Analysis Shows Better Survival With Allogeneic Transplantation vs Conventional Chemotherapy in Postremission Therapy for AML
In a prospective matched-pairs analysis reported in the Journal of Clinical Oncology, Stelljes et al in the German AML Cooperative Group compared outcomes with allogeneic stem cell transplantation vs conventional postremission chemotherapy in patients aged < 60 years with acute myeloid leukemia in first complete remission. They found that stem cell transplantation was associated with significantly better overall survival, including in patients with abnormal karyotype and those aged 45 to 69 years.